Heart & Cardiovascular Stack: Evidence and Comparison

What does this guide compare?

A lipid laboratory result, a blood-pressure change and prevention of a cardiovascular event are different outcomes.

This collection compares products discussed around one topic. It is not a protocol to take in full. Links to individual profiles appear after the article.

Which products are compared?

Fish Oil (EPA/DHA), CoQ10/Ubiquinol, Magnesium, Vitamin K2 (MK-4, MK-7), Vitamin D3 (Cholecalciferol).

Individual profiles describe formulation, source-reported amounts, tolerability and interactions. Those details remain ingredient-specific. An amount studied alone is not automatically appropriate in a combination.

How do their roles differ?

Fish oil, CoQ10, magnesium, vitamin K2 and vitamin D3 are the members of this comparison. Triglyceride changes, blood pressure, heart-failure symptoms and prevention of cardiovascular events are distinct outcomes. The omega-3 evidence below cannot be extended to every member, and a nutrient’s biological role does not establish that the full combination prevents a heart attack. [1], [2]

Selected ingredient studies and their limits

These examples compare distinct preparations and outcomes. Their schedules describe research and are not a regimen to combine.

Magnesium. nutritional adequacy and symptom treatment are different questions. In a 94-person trial, 520 mg elemental magnesium as an oxide complex at bedtime for 4 weeks did not outperform placebo for nocturnal leg-cramp frequency. That studied amount exceeds the U.S. adult supplemental upper limit of 350 mg/day and is not a routine target. For high-blood-pressure risk, FDA permits only a qualified claim because the supporting evidence is inconsistent and inconclusive. [5], [6], [7]

Vitamin D3. deficiency care is distinct from giving an unselected population extra vitamin D. VITAL assigned 25,871 adults to 2,000 IU daily or placebo and did not show prevention of major cardiovascular events. Its fracture analysis also found no reduction in total fractures. These findings do not rule out treatment of a diagnosed deficiency; they limit blanket prevention claims for generally healthy midlife and older adults. [8], [9], [10]

Vitamin K2. activation of vitamin-K-dependent proteins explains biological interest, but a change in a protein marker is not evidence that a product prevents fractures or cardiovascular events. MK-4 and MK-7 are different preparations. The adequate intake for total vitamin K is not an established MK-7 supplement dose, and vitamin K can materially alter warfarin treatment. [11]

CoQ10. Q-SYMBIO studied 420 people with moderate-to-severe heart failure: 100 mg three times daily for two years, alongside standard treatment. The 16-week endpoints were negative; the two-year composite cardiovascular endpoint occurred in 15% versus 26% with placebo. This treatment context does not establish prevention in healthy people or general lifespan extension. [14]

What does the research show?

Why is “omega-3” not a single intervention?

The composite included cardiovascular death, heart attack, stroke, coronary revascularization and unstable angina. These were not head-to-head trials of EPA versus EPA/DHA: populations, formulations, comparators and follow-up differed. They do not justify recreating a prescription amount with retail capsules. Both trials were industry-funded. [12], [13]

Heart-rhythm signals matter too: REDUCE-IT reported hospitalization for atrial fibrillation or flutter in 3.1% versus 2.1%; STRENGTH reported investigator-identified new atrial fibrillation in 2.2% versus 1.3%. Those are different outcomes, not directly comparable rates. [12], [13]

Omega-3 trials differ substantially by dose, formulation and baseline cardiovascular risk. Prescription EPA findings cannot simply be assigned to fish-oil, krill-oil or algal-oil bottles. In the 2025 DO-HEALTH post hoc analysis of 777 older adults, omega-3 treatment affected several methylation clocks. This exploratory surrogate finding did not demonstrate longer survival or validate a full longevity stack. [1][2]

An observational association, a laboratory finding and a perceived benefit answer different questions. Randomized trials need their comparator, duration and population kept in view. An inconclusive result does not establish that an effect is impossible; it limits the claim that can be made.

Which overlaps and risks matter?

Cautions and interactions

The EPA-plus-DHA content differs from total oil weight. Cod liver oil also adds vitamins A and D. High-dose cardiovascular trials have reported atrial fibrillation signals, and medication review remains relevant. Oxidation, storage and declared formulation matter; a larger oil capsule is not necessarily a larger studied exposure. [1][2]

A complete product list includes prescription medicines, nonprescription products and supplements. Combination formulas can conceal duplicate ingredients. Timing and spacing from a medicine should follow its labeling and pharmacist guidance; this collection does not supply a universal timetable.

Regulatory status

In the United States, FDA does not approve dietary supplements for safety and effectiveness before marketing. In Canada, a natural health product requires a product licence before sale; its NPN or DIN-HM must match the finished product. An ingredient name or inclusion in this collection does not establish that every product or claim is authorized. Authorization also does not validate the complete combination. [3], [4]

What should be recorded and how should changes be interpreted?

Doserly brings dose logs, symptoms and routine changes together. For this collection, useful observations include EPA/DHA amounts, formulation, tolerability, medication changes and clinician-interpreted lipid results.

• Doses and adherence: record the formulation, amount actually taken, timing and missed doses so observations have context.
• Potential benefits and tolerability: compare consistent symptoms or measurements over time alongside sleep, food and activity changes. Personal trends help evaluate the experience without proving causal efficacy.
• Product list: maintain the full product list for review with a pharmacist or clinician.
• AI monthly reports: summarize recorded doses, symptoms and trends to prepare for a discussion. Reports depend on the data entered and are not a diagnosis or an instruction to change treatment.

Explore the topic further

Common questions

Can ordinary fish oil claim the REDUCE-IT result?

No. REDUCE-IT tested prescription icosapent ethyl in a selected high-risk population on statins. That result does not establish equivalent benefit from a retail EPA/DHA capsule. [12]

Does comparing REDUCE-IT with STRENGTH prove one formulation is superior?

No. They were separate trials with different preparations and comparators, not a direct head-to-head comparison. Their different results show why “omega-3” is too broad a treatment label. [12][13]

Do higher amounts always mean greater cardiovascular benefit?

No. Benefit depends on the exact intervention and population; atrial-fibrillation signals also matter. These trials do not define a general supplement dose for everyone. [12][13]

Glossary

Terms for interpreting the comparisons.

Formulation

The exact preparation, including its ingredients, their forms and labeled amounts.

Study population

The people included in a study; their characteristics limit where its result applies.

Comparator

The placebo, treatment or condition used as the comparison.

Measured outcome

What the study evaluates, such as a symptom, laboratory result or clinical event.

Overlap

The same ingredient appearing in more than one product used together.

How was this guide researched?

Sources and limits

This AI-assisted educational guide compares the cited public references. Findings remain tied to the ingredients, preparations and populations studied. It is not a systematic review or independent medical peer review. Doserly develops a commercial tracking app. Illustrations explain concepts; app screens show example data. Report a correction with its source to Doserly support.

Explore the sources